KING OF PRUSSIA, Pa., Oct. 3 /PRNewswire/ -- Prism Pharmaceuticals, Inc., a privately-held, specialty pharmaceutical company committed to developing and commercializing acute care cardiovascular products, announced today the appointment of Maurits W. Geerlings, MD, MBA, to the position of Vice President, Business Development.
"I am pleased to welcome Dr. Geerlings to this important business development role at Prism because he brings a tremendous amount of relevant industry experience and relationships to the Company," said Warren Cooper, President and CEO of Prism. "Maurits shares our belief that significant opportunities exist to deliver better solutions to therapeutic challenges in the acute care setting and will further strengthen our focus on market need- based pipeline expansion and partnering."
Dr. Geerlings has more than 15 years of industry experience, including a strong entrepreneurial background and business development expertise spanning cardiology, oncology, and neurology. Prior to joining Prism, Dr. Geerlings served in business development roles at Cephalon, Inc. and Alexion Pharmaceuticals, Inc. Dr. Geerlings was a co-founder of Actinium Pharmaceuticals where he was responsible for fundraising, research & development, government affairs and corporate development. He received his medical degree from The University of Utrecht in the Netherlands and his Masters in Business Administration from The George Washington University in Washington, D.C.
About Prism Pharmaceuticals, Inc.
Prism, founded in September 2004 and based in King of Prussia, Pennsylvania, is a specialty pharmaceutical company committed to developing and commercializing acute care cardiovascular products. For further information, visit www.prismpharma.com.
CONTACT: Mike Beyer of Sam Brown Inc., +1-773-463-4211, or
email@example.com, for Prism Pharmaceuticals, Inc.
Web site: http://www.prismpharma.com/